Parkville, MO, United States
Parkville, MO, United States

University Park is the postal address used by Pennsylvania State University for its flagship campus in State College and adjacent College Township, Pennsylvania. It is not an incorporated community but exists as a postal address, with the accompanying zip code of 16802, for ease of mail delivery and to distinguish on-campus from off-campus addresses. Almost all of University Park sits within the borough of State College; the northeastern part of campus is within College Township. The campus post office was designated "University Park, Pennsylvania" in 1953 by Penn State president Milton Eisenhower, after what was then Pennsylvania State College was upgraded to university status.University Park sits within the State College Metropolitan Statistical Area , which encompasses all of Centre County, Pennsylvania. The ZCTA for ZIP code 16802 had a population of 12,764 at the 2010 census.The campus is served by the Penn State University Police.Federally, the University Park campus is part of Pennsylvania's 5th congressional district, represented by Republican Glenn "G.T." Thompson, elected in 2008. Wikipedia.

SEARCH FILTERS
Time filter
Source Type

News Article | April 17, 2017
Site: www.prweb.com

LearnHowToBecome.org, a leading resource provider for higher education and career information, has analyzed more than a dozen metrics to rank Missouri’s best universities and colleges for 2017. Of the 40 four-year schools on the list, Washington University in St. Louis, Saint Louis University, Maryville University of Saint Louis, William Jewell College and Rockhurst University were the top five. 14 two-year schools also made the list, and State Fair Community College, Crowder College, Jefferson College, East Central College and State Technical College of Missouri were ranked as the best five. A full list of the winning schools is included below. “The schools on our list have created high-quality learning experiences for students in Missouri, with career outcomes in mind,” said Wes Ricketts, senior vice president of LearnHowToBecome.Org. “They’ve shown this through the certificates and degrees that they offer, paired with excellent employment services and a record of strong post-college earnings for grads.” To be included on the “Best Colleges in Missouri” list, schools must be regionally accredited, not-for-profit institutions. Each college is also appraised on additional data that includes annual alumni salaries 10 years after entering college, employment services, student/teacher ratio, graduation rate and the availability of financial aid. Complete details on each college, their individual scores and the data and methodology used to determine the LearnHowToBecome.org “Best Colleges in Missouri” list, visit: The Best Four-Year Colleges in Missouri for 2017 include: Avila University Baptist Bible College Calvary Bible College and Theological Seminary Central Methodist University-College of Liberal Arts and Sciences College of the Ozarks Columbia College Culver-Stockton College Drury University Evangel University Fontbonne University Hannibal-LaGrange University Harris-Stowe State University Kansas City Art Institute Lincoln University Lindenwood University Maryville University of Saint Louis Midwestern Baptist Theological Seminary Missouri Baptist University Missouri Southern State University Missouri State University-Springfield Missouri University of Science and Technology Missouri Valley College Missouri Western State University Northwest Missouri State University Park University Rockhurst University Saint Louis University Southeast Missouri State University Southwest Baptist University Stephens College Truman State University University of Central Missouri University of Missouri-Columbia University of Missouri-Kansas City University of Missouri-St Louis Washington University in St Louis Webster University Westminster College William Jewell College William Woods University Missouri’s Best Two-Year Colleges for 2017 include: Crowder College East Central College Jefferson College Lake Career and Technical Center Mineral Area College Missouri State University - West Plains Moberly Area Community College North Central Missouri College Ozarks Technical Community College St. Charles Community College State Fair Community College State Technical College of Missouri Texas County Technical College Three Rivers Community College About Us: LearnHowtoBecome.org was founded in 2013 to provide data and expert driven information about employment opportunities and the education needed to land the perfect career. Our materials cover a wide range of professions, industries and degree programs, and are designed for people who want to choose, change or advance their careers. We also provide helpful resources and guides that address social issues, financial aid and other special interest in higher education. Information from LearnHowtoBecome.org has proudly been featured by more than 700 educational institutions.


News Article | June 14, 2017
Site: www.eurekalert.org

University Park, PA -- A newly described protein could be an effective target for combatting drug-resistant malaria parasites. The protein, the transcription factor PfAP2-I, regulates a number of genes involved with the parasite's invasion of red blood cells, a critical part of the parasite's complex life cycle that could be targeted by new antimalarial drugs. A paper describing the protein PfAP2-I and its role in the invasion process appears June 14, 2017 in the journal Cell Host & Microbe. "The reality is that there are resistant parasites to every known antimalarial drug," said Manuel Llinás, professor of biochemistry and molecular biology at Penn State University and lead author of the paper. "We need new drugs targeting different aspects of parasite biology." Nearly half of the world's population lives in areas at risk of transmitting malaria, a serious and sometimes fatal disease that produces symptoms such as fevers, chills, and flu-like illness. According to the World Health Organization, over 212 million cases of malaria were reported in 2015, with an estimated 429,000 deaths, the majority of which occur in young children in sub-Saharan Africa. Malaria is caused by Plasmodium parasites, which have a complex 3-stage life cycle. After a parasite-carrying mosquito bites a person, the parasite infects liver cells, where it grows and multiplies. The parasites then invade red blood cells, where they multiply further, releasing daughter parasites, or merozoites, that in turn must invade new red blood cells. Symptoms of malaria are expressed during this cyclical 48-hour red blood cell life-stage. "Quite simply, if you prevent the parasite from invading red blood cells, you prevent any disease," says Llinás. "We want to understand how this invasion process is regulated at the genetic level. One of the unique features about Plasmodium is that it has very few transcription factors -- proteins that bind to specific DNA sequences to direct which genes should be turned on and when. Most multi-celled organisms have hundreds of these regulators, but it turns out, so far as we can recognize, the parasite has a single family of transcription factors called Apicomplexan AP2 proteins. One of these transcription factors is PfAP2-I." PfAP2-I is the first known regulator of invasion genes in Plasmodium falciparum -- the species that causes the deadliest form of malaria. In total, PfAP2-I specifically regulates over 150 genes, eighteen percent of which are known to be involved in the red blood cell invasion process. The new study also indicates that PfAP2-I likely recruits another protein, Bromodomain Protein 1 (PfBDP1), which was previously shown to be involved in the invasion of red blood cells. The two proteins may work together to regulate gene transcription during this critical stage of infection. "Red blood cell invasion has been seriously considered for a long time as a candidate for antimalarial vaccines," says Llinás. "Many proteins that are found on the surface of the merozoite -- proteins that help the parasite bind to and pull itself inside of a new red blood cell -- have been targeted with vaccines, but they've all failed. Why? The surface proteins are very redundant, so unless you interfere with all of them, you can't block invasion. But disrupting PfAP2-I would prevent the invasion program from ever getting turned on in the first place." Instead of targeting the merozoite surface proteins with a vaccine, a new drug could focus solely on inhibiting PfAP2-I. Preventing PfAP2-I from binding to DNA and initiating the expression of invasion genes, or preventing PfAP2-I from recruiting other important proteins like PfBDP1, would stop an infection before it even reaches the red blood cell stage. Because PfAP2-I does not have parallels in humans, a drug targeting this transcription factor may have the added benefit of specificity, making it safer with fewer potential side-effects in humans. "Now that we know how the invasion process is regulated," says Llinás, "we have a completely new angle for targeting the parasite through pharmacological intervention." In addition to Llinás, the research team includes Joana Santos, Gabrielle Josling, Philipp Ross, and Lindsey Orchard, postdoctoral researchers and research assistants at Penn State at the time of the research, and Preeti Joshi, Tracey Campbell, Ariel Schieler, and Ileana Cristea at Princeton University. The research was funded by the U.S. National Institutes of Health, the Arnold and Mabel Beckman Foundation, and the Princeton Center for Quantitative Biology. Additional support was provided by the Swiss National Science Foundation, EMBO, the Natural Sciences and Engineering Research Council of Canada, the New Jersey Commission on Cancer Research, the American Heart Association, and the Huck Institutes of the Life Sciences. A colorized electron micrograph of a malaria-causing Plasmodium parasite (right) attaching to and invading a human red blood cell. The inset shows the attachment point at higher magnification. Credit: National Institute of Allergy and Infectious Diseases, NIH


News Article | June 6, 2017
Site: www.eurekalert.org

University Park, PA -- A newly discovered Jupiter-like world is so hot that even its nights are like the flame of a welding torch. Planet KELT-9b is hotter than most stars. With a day-side temperature of more than 7,800 degrees Fahrenheit (4,600 Kelvin), it is only about 2,000 degrees Fahrenheit (1,200 Kelvin) cooler than our own sun. "At these temperatures, the fundamental component of KELT-9b's atmosphere will be blasted apart into individual atoms during the day," said Thomas Beatty, a research scientist at Penn State University and a coauthor on the study. This element is hydrogen, which usually exists as a pair of two hydrogen atoms. "Then as night falls, all those hydrogen atoms will try and get back together, creating an inferno at dusk," he said. "On Earth, this same process is used to create one of the hottest welding flames known." In this week's issue of the journal Nature, an international research team including astronomers from The Ohio State University, Vanderbilt University, and Penn State University describes this planet and some of its very unusual features. For instance, it is a gas giant 2.8 times more massive than Jupiter, but only half as dense because the extreme radiation from its host star has caused its atmosphere to puff up like a balloon. And because it is tidally locked to its star -- as the Moon is to Earth -- the day side of the planet is perpetually bombarded by radiation from its star and, as a result, is so hot that molecules such as water, carbon dioxide, methane and hydrogen can't form there. The properties of the night side are still mysterious -- molecules may be able to form there, but probably only temporarily. "It's a planet by any of the typical definitions based on mass, but its atmosphere is almost certainly unlike any other planet we've ever seen just because of the temperature of its day side," said Scott Gaudi, professor of astronomy at The Ohio State University and a leader of the study. KELT-9b orbits a star, dubbed KELT-9, that is more than twice as large and nearly twice as hot as our sun. Keivan Stassun, a professor of physics and astronomy at Vanderbilt who directed the study with Gaudi said, "KELT-9 radiates so much ultraviolet radiation that it may completely evaporate the planet. Or, if gas giant planets like KELT-9b possess solid rocky cores as some theories suggest, the planet may be boiled down to a barren rock, like Mercury." That is, if the star doesn't grow to engulf it first. "KELT-9 will swell to become a red giant star in about a billion years," said Stassun. "The long-term prospects for life, or real estate for that matter, on KELT-9b are not looking good." Given that its atmosphere is constantly blasted with high levels of ultraviolet radiation, the planet may even be shedding a tail of evaporated planetary material like a comet, Gaudi added. While Gaudi and Stassun spend a lot of time developing missions designed to find habitable planets in other solar systems, the scientists said there's a good reason to study worlds that are unlivable in the extreme. "As has been highlighted by the recent discoveries from the MEarth collaboration, the planet around Proxima Centauri, and the astonishing system discovered around TRAPPIST-1, the astronomical community is clearly focused on finding Earthlike planets around small, cooler stars like our sun. They are easy targets and there's a lot that can be learned about potentially habitable planets orbiting very-low-mass stars in general. On the other hand, because KELT-9b's host star is bigger and hotter than the sun, it complements those efforts and provides a kind of touchstone for understanding how planetary systems form around hot, massive stars," Gaudi said. Stassun added, "As we seek to develop a complete picture of the variety of other worlds out there, it's important to know not only how planets form and evolve, but also when and under what conditions they are destroyed." The astronomers hope to take a closer look at KELT-9b with other telescopes--including Spitzer, the Hubble Space Telescope (HST), and eventually the James Webb Space Telescope. Observations with HST would enable them to see if the planet really does have a cometary tail, and allow them to determine how much longer that planet will survive its current hellish condition. "Looking at KELT-9b with Hubble will be a once-in-a-lifetime opportunity. It's the only place in the universe where we can watch an entire planet go through a phase-change from day to night," said Beatty, who is leading the efforts to observe KELT-9b in more detail. How was this new planet found? In 2014, astronomers using the KELT-North telescope at Winer Observatory in Arizona noticed a tiny drop in the star's brightness--only about half of one percent--indicating that a planet may have passed in front of the star. The brightness dipped once every 1.5 days, which means the planet completes a "yearly" circuit around its star every 1.5 days. Subsequent observations confirmed the signal to be due to a planet, and revealed it to be what astronomers call a "hot Jupiter" -- the ideal kind of planet for the KELT telescopes to spot. KELT is short for "Kilodegree Extremely Little Telescope." Astronomers at Ohio State, Vanderbilt University, and Lehigh University jointly operate two KELTs (one each in the Northern and Southern Hemispheres) in order to fill a large gap in the available technologies for finding extrasolar planets. Other telescopes are designed to look at very faint stars in much small sections of the sky, and at very high resolution. The KELTs, in contrast, look at millions of very bright stars at once, over broad sections of sky, and at low resolution -- a low-cost means of planet hunting using mostly off-the-shelf technology. A traditional astronomical telescope costs millions of dollars to build, while the hardware for a KELT telescope runs less than $75,000. The study's coauthor from Penn State is Thomas Beatty, of the Department of Astronomy and Astrophysics. American partner institutions include the Ohio State University, Vanderbilt University, Fisk University, the Harvard-Smithsonian Center for Astrophysics, Las Cumbres Observatory Global Telescope Network, University of Notre Dame, Lehigh University, NASA Ames Research Center, Bay Area Environmental Research Institute, Swarthmore College, IPAC, Brigham Young University, University of California-Santa Cruz, University of Wyoming, Louisiana State University, University of Louisville, Spot Observatory in Nashville, Westminster College, Kutztown University, University of Hawaii, University of Washington, Texas A&M University, Wellesley College, and Winer Observatory in Sonoita, AZ. International team members are from Denmark, Italy, Japan, Portugal, Switzerland, Australia, Germany and South Africa. The study was largely funded by the National Science Foundation (NSF) through an NSF CAREER Grant, NSF PAARE Grant and an NSF Graduate Research Fellowship. Additional support came from NASA via the Jet Propulsion Laboratory and the Exoplanet Exploration Program; the Harvard Future Faculty Leaders Postdoctoral Fellowship; Theodore Dunham, Jr., Grant from the Fund for Astronomical Research; and the Japan Society for the Promotion of Science.


Grant
Agency: European Commission | Branch: H2020 | Program: MSCA-RISE | Phase: MSCA-RISE-2015 | Award Amount: 891.00K | Year: 2016

Our proposal aims to carry out a systematic interdisciplinary study of carbon-based nanomaterials, such as: carbon fluoroxide nanoparticles, carbon nanotubes, graphene and nanodiamonds for advanced theranostic application. Their uptake efficiency and specific localization in biological cells depending on intentionally designed surface chemistry will be studied in details. Extremely rich physico-chemical properties of the carbon-based nanomaterials will allow their application as multi-modal bio-imaging agents. Indeed, in addition to their well-known remarkable luminescent properties, two original bio-imaging approaches based on photo-induced electrical and acoustic effects will be developed in frames of our project. Moreover, the photo-exciting sources used for the bio-imaging purpose will be simultaneously used for therapy of cancer cells and tissues containing the carbon nanomaterials. Strongly complementary research experiences of the international partners involved in this project as well as high degree of cooperative integration between them will allow a deep scientific study of the theranostic potential of the carbon nanomaterials. Finally, active participation of the Ray Technique Ltd industrial company in the project consortium will allow building of strategies for economic realizations of the innovative achievements succeeded by the partners.


A series of resorcylic acid macrolactams, nitrogen analogues of the naturally occurring macrolactone radicicol, have been prepared by chemical synthesis and evaluated as inhibitors of heat shock protein 90 (Hsp90), an emerging attractive target for novel cancer therapeutic agents. The synthesis involves, as key steps, ring opening of an isocoumarin intermediate, followed by a ring-closing metathesis reaction to form the macrocycle. Subsequent manipulation of the ester group into a range of amides allows access to a range of new macrolactams following deprotection of the two phenolic groups. These new resorcylic acid lactams exhibit metabolic stability greater than that of related lactone counterparts, while co-crystallization of three macrolactams with the N-terminal domain ATP site of Hsp90 confirms that they bind in a similar way to the natural product radicicol and to our previous synthetic lactone analogues. Interestingly, however, in the case of the N-benzylamide, additional binding to a hydrophobic pocket of the protein was observed. In biological assays, the new macrocyclic lactams exhibit a biological profile equivalent or superior to that of the related lactones and show the established molecular signature of Hsp90 inhibitors in human colon cancer cells.


Previous studies have demonstrated poor sensitivity of guideline weight monitoring in predicting clinical deterioration of heart failure (HF). This study aimed to evaluate patterns of remotely transmitted daily weights in a high-risk HF population and also to compare guideline weight monitoring and an individualized weight monitoring algorithm. Consenting, consecutive, high-risk patients were provided with a mobile phone-based remote weight telemonitoring device. We aimed to evaluate population vs. individual weight variability, weight patterns pre- and post-events of clinical deterioration of HF, and to compare guideline weight thresholds with the HeartPhone algorithm in terms of sensitivity and specificity for such events. Of 87 patients recruited and followed for an average of 23.9 ± 12 weeks, 19 patients experienced 28 evaluable episodes of clinical deterioration of HF. Following a post-discharge decline, the population average weight remained stable for the follow-up period, yet the 7-day moving average of individual patients exceeded 2 kg in three-quarters of patients. Significant increases in weight were observed up to 4 days before HF events. The HeartPhone algorithm was significantly more sensitive (82%) in predicting HF events than guideline weight thresholds of 2 kg over 2-3 days (21%) and a 'rule of thumb' threshold of 1.36 kg over 1 day (46%). An individualized approach to weight monitoring in HF with the HeartPhone algorithm improved prediction of HF deterioration. Further evaluation of HeartPhone with and without other biomarkers of HF deterioration is warranted.


Molloy E.S.,Park University | Calabrese L.H.,Cleveland Clinic
Arthritis and Rheumatism | Year: 2012

Objective To evaluate the association of progressive multifocal leukoencephalopathy (PML) with immunosuppressive therapy for autoimmune rheumatic diseases (ARDs). Methods A Freedom of Information Act request was submitted for all cases of PML within the Food and Drug Administration Adverse Event Reporting System database. ARD cases were selected for further analysis. Results A total of 34 confirmed cases of PML in the setting of ARDs were identified: 17 had systemic lupus erythematosus, 10 had rheumatoid arthritis, 4 had vasculitis, and 3 had dermatomyositis. Fifteen of these patients were treated with one or more biologic agents: 14 received rituximab (RTX), 6 received anti-tumor necrosis factor (anti-TNF) therapy (5 treated with anti-TNF agent prior to RTX). Four RTX-treated patients were not receiving additional immunosuppressive therapy at the time of PML onset, other than an antimalarial drug and/or low-dose glucocorticoids; all others who were receiving a biologic agent were also receiving one or more synthetic disease-modifying agents. All but 1 patient receiving a biologic agent had at least 1 potential confounding factor for the diagnosis of PML. The remaining 19 confirmed cases of PML among ARD patients were treated with synthetic disease-modifying antirheumatic drugs only, 14 of whom had received an alkylating agent. Conclusion PML has been reported in patients with ARD treated with various immunosuppressive agents. The limitations of this study preclude definitive attribution of causality. While the paucity of confirmed cases recently exposed to anti-TNF therapy suggests a causal relationship is unlikely, a specific signal is emerging with regard to rituximab and PML. Although this is a rare adverse event associated with RTX therapy, the devastating nature of PML mandates continued vigilance, particularly in patients with current or prior exposure to an alkylating agent. Copyright © 2012 by the American College of Rheumatology.


The aim of this study was to examine the effect of blocking Toll-like receptor 2 (TLR2) in rheumatoid arthritis (RA) synovial cells. RA synovial tissue biopsies, obtained under direct visualization at arthroscopy, were established as synovial explant cultures ex vivo or snap frozen for immunohistology. Mononuclear cell cultures were isolated from peripheral blood and synovial fluid of RA patients. Cultures were incubated with the TLR1/2 ligand, Pam3CSK4 (200 ng, 1 and 10 μg/ml), an anti-TLR2 antibody (OPN301, 1 μg/ml) or an immunoglobulin G (IgG) (1 μg/ml) matched control. The comparative effect of OPN301 and adalimumab (anti-tumour necrosis factor alpha) on spontaneous release of proinflammatory cytokines from RA synovial explants was determined using quantitative cytokine MSD multiplex assays or ELISA. OPN301 penetration into RA synovial tissue explants cultures was assessed by immunohistology. Pam3CSK4 significantly upregulated interleukin (IL)-6 and IL-8 in RA peripheral blood mononuclear cells (PBMCs), RA synovial fluid mononuclear cells (SFMCs) and RA synovial explant cultures (P < 0.05). OPN301 significantly decreased Pam3CSK4-induced cytokine production of tumour necrosis factor alpha (TNF-α), IL-1β, IL-6, interferon (IFN)-γ and IL-8 compared to IgG control in RA PBMCs and SFMCs cultures (all P < 0.05). OPN301 penetration of RA synovial tissue cultures was detected in the lining layer and perivascular regions. OPN301 significantly decreased spontaneous cytokine production of TNF-α, IL-1β, IFN-γ and IL-8 from RA synovial tissue explant cultures (all P < 0.05). Importantly, the inhibitory effect of OPN on spontaneous cytokine secretion was comparable to inhibition by anti-TNFα monoclonal antibody adalimumab. These findings further support targeting TLR2 as a potential therapeutic agent for the treatment of RA.


Grant
Agency: NSF | Branch: Standard Grant | Program: | Phase: ANTARCTIC EARTH SCIENCES | Award Amount: 168.09K | Year: 2014

This project will involve examination of Glossopteridales, fossil plants from Upper Permian deposits, in samples from the central Transantarctic Mountains and Southern Victoria Land, Antarctica. The glossopterids are an important fossil group because they are possible ancestors to the flowering plants. Permian sedimentary rocks (295-270 Ma before present) are important because they record a time of rapid biotic change, as the Late Paleozoic Age ended and the Mesozoic greenhouse environment began. The proposed research will rely entirely on specimens collected during recent field excursions to the central Transantarctic Mountains (CTM; 2010?2011) and southern Victoria Land (SVL; 2012?2013). Only a few of the specimens have been studied, but already have yielded anatomically well-preserved glossopterids with a complete pollen cone, which has never been found before. Additionally, several seed-bearing structures, which have never before been observed in Antarctica, have been found in both CTM and SVL. The project will allow comparison of whole-plant fossil glossopterids from the CTM with other paleo-latitudes, and will document the floral diversity within and between two depositional basins (CTM & SVL) during a time of global change, with the overall goal of linking environmental changes with fossil morphology.

Broader impacts:
The Broader Impacts of this project will include mentoring undergraduates in research projects, at an institution with a substantial minority enrollment. Public outreach will focus on involving middle/high school students through the ?Expanding Your Horizons? programs in Kansas and Missouri, as well as interactive presentations at schools in the Kansas City Area. The lead PI is an early-career scientist at an institution that serves minorities.


Patent
Park University | Date: 2015-05-06

The current invention provides novel nitinol alloys, particularly, nitinol alloys containing a third metallic element referred to as ternary nitinol alloys. Accordingly, the current invention provides nitinol alloys including, but not limited to, Nickel-Titanium-Chromium (NiTiCr) and Nickel-Titanium-Tantalum (NiTiTa). The current invention also provides implants manufactured from the ternary nitinol alloys. The implants comprise the ternary nitinol alloys and are, optionally, surface treated to promote anti-thrombogenicity and biocompatibility, for example, through magnetoelectropolishing (MEP). Accordingly, the current invention provides nitinol alloys and implants comprising the nitinol alloys that reduce the risk of clotting due to stagnant blood flow, eliminate flushing, and minimize infection and damage to blood vessels.

Loading Park University collaborators
Loading Park University collaborators